MYC and Miyoshi myopathy: Moreover, the (18)-FDG PET metabolic tumor burden was shown to be associated with high-risk gene expression in MM [87]; however, a direct comparison between (18)-FDG-PET status, the expression of glycolysis genes, and MYC aberrations has not been reported yet.